Pivotal bioVenture Partners Fund I G.P., L.P. insider trades: Inozyme Pharma (INZY) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Pivotal bioVenture Partners Fund I G.P., L.P. reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 1, 2023 | INZY | ↑ Buy | 833,333 | $4.80 | $4.0M | Indirect | Aug 3, 2023 (2d) |
| Apr 19, 2022 | INZY | ↑ Buy | 1,070,000 | $3.69 | $3.9M | Indirect | Apr 20, 2022 (1d) |
| Jul 28, 2020 | INZY | ↑ Buy | 187,500 | $16.00 | $3.0M | Indirect | Jul 28, 2020 (0d) |
| Jun 30, 2020 | AKUS | ↑ Buy | 294,117 | $17.00 | $5.0M | Indirect | Jul 1, 2020 (1d) |
| Sep 28, 2018 | ETTX | ↑ Buy | 337,724 | $15.00 | $5.1M | Indirect | Oct 2, 2018 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Pivotal bioVenture Partners Fund I G.P., L.P.'s insider trades
Pivotal bioVenture Partners Fund I G.P., L.P. is an insider at Inozyme Pharma (INZY). Since Sep 28, 2018, it has reported 5 open-market purchases worth $21.0M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include conversions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every INZY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.